Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens
about
Possible future monoclonal antibody (mAb)-based therapy against arbovirus infectionsNonstructural Protein 1-Specific Immunoglobulin M and G Antibody Capture Enzyme-Linked Immunosorbent Assays in Diagnosis of Flaviviral Infections in HumansAn in-depth analysis of original antigenic sin in dengue virus infectionEstablishment of an Algorithm Using prM/E- and NS1-Specific IgM Antibody-Capture Enzyme-Linked Immunosorbent Assays in Diagnosis of Japanese Encephalitis Virus and West Nile Virus Infections in HumansThe Complexity of a Dengue Vaccine: A Review of the Human Antibody ResponseTetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2–16 Years in Asia and Latin AmericaDengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibodyThe Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and ImmunityStructural insights into the neutralization mechanism of a higher primate antibody against dengue virusStructural Analysis of a Dengue Cross-Reactive Antibody Complexed with Envelope Domain III Reveals the Molecular Basis of Cross-ReactivityThe Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and ImmunoprophylaxisCharacterization of the ectodomain of the envelope protein of dengue virus type 4: expression, membrane association, secretion and particle formation in the absence of precursor membrane protein.A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein.In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection.Genetic and phenotypic characterization of sylvatic dengue virus type 4 strainsAnalysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assayAntibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2Phage display approaches for the isolation of monoclonal antibodies against dengue virus envelope domain III from human and mouse derived libraries.Development of a humanized antibody with high therapeutic potential against dengue virus type 2Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccineCross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins.The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope proteinVariation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysisPartially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine.Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination.Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected].Dissection of antibody specificities induced by yellow fever vaccinationAntibody-mediated neutralization of flaviviruses: a reductionist view.Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases.The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.Antibodies against immature virions are not a discriminating factor for dengue disease severity.Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms.B-cell responses during primary and secondary dengue virus infections in humans.An Epitope-Substituted DNA Vaccine Improves Safety and Immunogenicity against Dengue Virus Type 2.Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive AntibodiesFormalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III.Recombinant Envelope-Proteins with Mutations in the Conserved Fusion Loop Allow Specific Serological Diagnosis of Dengue-Infections.
P2860
Q24289014-581608AF-C6D0-4F67-A00D-C85C9F026A0AQ24289099-89DF86E9-98F6-4090-8DA9-04A2AC237DE2Q24606493-8049434D-C9AD-4FEF-A955-B55D700AEBD7Q26700017-AD53D29A-F853-49B5-AF1A-461AB183A6D1Q26995782-A3EF39FF-5791-4FB5-9E0E-6EA0DBE4BCA8Q27468944-FB3EF19E-4412-4115-A8D4-497EB4A0C9B4Q27489654-68ACFF90-AECE-4BC4-AB05-9BE81AB7B885Q27491317-DF919A1C-F6AC-4DE1-9BDC-06EC9773FC3EQ27654848-1D19F71F-2983-4795-BACB-674D6F6A1BD9Q27675965-96C966DB-808E-4E34-A7C0-7CF06277DF87Q27678419-FF8A062F-A5A0-45E6-8A30-3E940526913EQ28804225-75F05E01-88FD-4D95-8838-C11C9AF6DDDEQ33784307-C1EC18D9-800D-4915-AF86-D1FF7A385A89Q33802834-62F635BA-EF16-44FB-9B5A-4216A39CB69BQ33945441-25B97CCB-C5BA-4915-A263-0AFAEEEDEAB3Q34104330-CA2A4E46-27C1-4B5C-94AA-961F0C8BEB0EQ34123956-13C3AE28-575C-419A-B4AE-B1CDB00C5CAAQ34202698-91F0E0F9-30C5-4820-967B-F2DBBE2935F2Q34226542-66F1F95C-44A2-47F0-987D-9F40B06A8EEFQ34260219-AD81FFB8-21DC-45E3-B379-B19A6D9F0090Q34262245-3A514A6D-537C-43E6-9D0B-7570DBA2E169Q34354665-7B7ADC7A-99F2-4AC0-87C5-DFC49D40A2FEQ34386384-B31F9E2A-0FE8-4FEB-99B0-AB02C34F2D6CQ34423720-B0A5BF4F-28DB-4315-A17B-091AF88746D8Q34431587-6595F51B-202A-4404-820A-627DDF01D442Q34593818-032F569D-8EB8-4B21-99B2-5DEA1972CBDBQ34594111-EA9C7243-B7F9-4C74-860D-B5FAA1FA53A9Q34607919-C8D50A91-996D-4566-A060-FC279A88BBFEQ34789343-1C27F6FE-BE64-4058-829F-9F2BB826139AQ34999617-E5BE8CF9-4E2C-428B-AFB3-FB2D5A41C8EEQ34999885-EB9CBB11-4B79-4697-8695-4D335F3428E7Q35069160-F1C6AEA7-49B4-4EB5-B0B7-5E39CFC38EFBQ35168403-09BF5B4E-7919-4E04-8305-C48000E86DB1Q35531167-CC33EACE-6C15-4BAA-999F-821236D89FC1Q35567408-BE134226-2043-4C25-A52B-779D467A3464Q35681101-6C437BB7-2A35-4CEB-8FEE-2548029B5A97Q35756190-D7255972-17AF-4FE6-8056-72D620976553Q35758626-E3903C59-0549-486C-86DA-0516B51EB5C2Q35818688-26CE6045-5257-41A6-9B91-67525FD0FF46Q35840849-28FF4824-6C70-46ED-A190-61216F7E5568
P2860
Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Humoral Immune Responses of De ...... 2 Virus-Like Particle Antigens
@ast
Humoral Immune Responses of De ...... 2 Virus-Like Particle Antigens
@en
Humoral Immune Responses of De ...... 2 Virus-Like Particle Antigens
@nl
type
label
Humoral Immune Responses of De ...... 2 Virus-Like Particle Antigens
@ast
Humoral Immune Responses of De ...... 2 Virus-Like Particle Antigens
@en
Humoral Immune Responses of De ...... 2 Virus-Like Particle Antigens
@nl
prefLabel
Humoral Immune Responses of De ...... 2 Virus-Like Particle Antigens
@ast
Humoral Immune Responses of De ...... 2 Virus-Like Particle Antigens
@en
Humoral Immune Responses of De ...... 2 Virus-Like Particle Antigens
@nl
P2093
P2860
P3181
P1433
P1476
Humoral Immune Responses of De ...... 2 Virus-Like Particle Antigens
@en
P2093
Gwong-Jen J Chang
Holly R Hughes
Mark J Delorey
Wayne D Crill
P2860
P3181
P356
10.1371/JOURNAL.PONE.0004991
P407
P5008
P577
2009-01-01T00:00:00Z